Celldex Therapeutics, Inc. (CLDX) Receives $7.63 Consensus Target Price from Analysts

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has been given a consensus rating of “Buy” by the nine ratings firms that are currently covering the stock. Two equities research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $7.63.

Several research firms recently weighed in on CLDX. HC Wainwright reissued a “buy” rating and set a $6.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, March 15th. Jefferies Group LLC dropped their price target on Celldex Therapeutics from $5.00 to $4.00 and set a “hold” rating on the stock in a research report on Wednesday, March 15th. Zacks Investment Research lowered Celldex Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, November 29th. Finally, Aegis reissued a “buy” rating on shares of Celldex Therapeutics in a research report on Tuesday.

A number of hedge funds and other institutional investors have recently modified their holdings of CLDX. Federated Investors Inc. PA increased its position in shares of Celldex Therapeutics by 16.9% in the fourth quarter. Federated Investors Inc. PA now owns 528,730 shares of the biopharmaceutical company’s stock worth $1,872,000 after buying an additional 76,364 shares during the period. FMR LLC increased its position in shares of Celldex Therapeutics by 40.3% in the fourth quarter. FMR LLC now owns 19,327,111 shares of the biopharmaceutical company’s stock worth $68,418,000 after buying an additional 5,555,595 shares during the period. Wells Fargo & Company MN increased its position in shares of Celldex Therapeutics by 31.2% in the third quarter. Wells Fargo & Company MN now owns 78,383 shares of the biopharmaceutical company’s stock worth $317,000 after buying an additional 18,661 shares during the period. KLP Enterprises LLC purchased a new position in shares of Celldex Therapeutics during the fourth quarter worth approximately $24,302,000. Finally, Columbia Wanger Asset Management LLC increased its position in shares of Celldex Therapeutics by 113.1% in the fourth quarter. Columbia Wanger Asset Management LLC now owns 6,195,855 shares of the biopharmaceutical company’s stock worth $21,933,000 after buying an additional 3,288,332 shares during the period. Hedge funds and other institutional investors own 55.99% of the company’s stock.

Shares of Celldex Therapeutics (NASDAQ:CLDX) opened at 3.33 on Monday. The stock’s market capitalization is $410.30 million. The company’s 50 day moving average price is $3.43 and its 200 day moving average price is $3.65. Celldex Therapeutics has a one year low of $2.85 and a one year high of $5.13.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Tuesday, March 14th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.04. The firm had revenue of $1.87 million for the quarter, compared to analyst estimates of $1.10 million. Celldex Therapeutics had a negative return on equity of 51.46% and a negative net margin of 1,923.41%. Celldex Therapeutics’s quarterly revenue was up 4.5% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.33) earnings per share. On average, equities analysts expect that Celldex Therapeutics will post ($1.20) earnings per share for the current year.

WARNING: This news story was posted by Web Breaking News and is the property of of Web Breaking News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at http://www.webbreakingnews.com/2017/03/25/celldex-therapeutics-inc-cldx-receives-7-63-consensus-target-price-from-analysts.html.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

5 Day Chart for NASDAQ:CLDX

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Nike Suspends Relationship with Maria Sharapova
Nike Suspends Relationship with Maria Sharapova
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Ron Washington Leaves Texas Rangers Due to an Affair
Ron Washington Leaves Texas Rangers Due to an Affair
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Tony Stewart Case Going to the Grand Jury
Tony Stewart Case Going to the Grand Jury
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder


Leave a Reply

 
© 2006-2017 Web Breaking News.